Skip to main content

Angioplasty

1
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Shockwave Medical
Shockwave MedicalCA - Santa Clara
1 program
1
Metricath Gemini SystemPhase 21 trial
Active Trials
NCT00399646Completed145Est. Mar 2009
Abbott
AbbottABBOTT PARK, IL
2 programs
XIENCE PRIME Everolimus Eluting Coronary Stent SystemN/A1 trial
XIENCE V® Everolimus Eluting Coronary Stent SystemN/A1 trial
Active Trials
NCT01894152Completed2,002Est. Oct 2019
NCT01249027Completed2,605Est. Jan 2017
Eisai
EisaiChina - Liaoning
1 program
fospropofol disodiumPHASE_31 trial
Active Trials
NCT00209547Completed110Est. Mar 2005

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Eisaifospropofol disodium
Shockwave MedicalMetricath Gemini System
AbbottXIENCE PRIME Everolimus Eluting Coronary Stent System
AbbottXIENCE V® Everolimus Eluting Coronary Stent System

Clinical Trials (4)

Total enrollment: 4,862 patients across 4 trials

NCT00209547Eisaifospropofol disodium

Study to Assess Safety and Efficacy of AQUAVAN® Injection for Sedation During Cardiac Catheterization

Start: Feb 2004Est. completion: Mar 2005110 patients
Phase 3Completed
NCT00399646Shockwave MedicalMetricath Gemini System

Evaluation of the Metricath Gemini System, a Device Intended to Make Arterial Measurements and Perform Angioplasty Dilations.

Start: Nov 2005Est. completion: Mar 2009145 patients
Phase 2Completed
NCT01894152AbbottXIENCE PRIME Everolimus Eluting Coronary Stent System

XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study

Start: Jul 2013Est. completion: Oct 20192,002 patients
N/ACompleted
NCT01249027AbbottXIENCE V® Everolimus Eluting Coronary Stent System

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

Start: Nov 2010Est. completion: Jan 20172,605 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.